Canyon Pharmaceuticals

Canyon Pharmaceuticals is a privately held specialty biopharmaceutical company that holds worldwide rights to the direct thrombin inhibitor desirudin, approved in the US and Europe for prevention of blood clots in patients undergoing major orthopedic surgery such as hip or knee replacement, and has supported post‑approval clinical work (e.g., the DESIR-ABLE multicenter study) demonstrating an acceptable safety profile without major bleeding events in a broad, high‑risk hospitalized population.[1] It also holds rights to pegmusirudin, a pegylated direct thrombin inhibitor with longer duration of action, which appears to be in development rather than widely commercialized.[1]